Fangxiao Hu

This study designs a CD33-mesothelin loop CAR to enhance iNK cell efficacy against AML by avoiding fratricide and improving cytotoxicity.

The paper generates siTNK cells from hPSCs using a synthetic TCR complex, showing tumor-specific cytotoxicity and anti-tumor activity in xenograft models.

This study generates CD7 CAR-NK cells from pluripotent stem cells that avoid fratricide and effectively suppress T-cell malignancies in xenograft models.

This study develops a novel CAR-NK cell therapy using pluripotent stem cell-derived NK progenitors that persist in blood and eliminate minimal residual disease.

This study develops a three-step method to generate high-yield CAR NK cells from umbilical cord blood CD34+ HSPCs, reducing CAR engineering costs and enabling therapeutic applications.